• BridgeBio Oncology Therapeutics Inc BBOT.OQ reported a quarterly adjusted loss of 53 cents​​ per share for the quarter ended March 31. The mean expectation of ten analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -62 cents to -49 cents per share.

• Reported revenue was zero​; analysts expected zero.

• BridgeBio Oncology Therapeutics Inc's reported EPS for the quarter was a loss of 53 cents​.

• The company reported a quarterly loss of $42.11 million.

• BridgeBio Oncology Therapeutics Inc shares had fallen by 11.8% this quarter and lost 37.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.00, about 64.7% above its last closing price of $8.13

This summary was machine generated from LSEG data May 12 at 10:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)